Refine
Year of publication
Has Fulltext
- yes (1237)
Is part of the Bibliography
- no (1237)
Keywords
- Heavy Ion Experiments (20)
- BESIII (16)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- e +-e − Experiments (11)
- LHC (9)
- Branching fraction (8)
- Heavy-ion collision (6)
- Quarkonium (6)
- Hadronic decays (5)
- Particle and Resonance Production (5)
- ALICE experiment (4)
- Branching fractions (4)
- Charm physics (4)
- Collective Flow (4)
- Electroweak interaction (4)
- Exotics (4)
- Jets (4)
- Lepton colliders (4)
- QCD (4)
- Quark-Gluon Plasma (4)
- Spectroscopy (4)
- ALICE (3)
- Charm Physics (3)
- Charmed mesons (3)
- Experimental nuclear physics (3)
- Experimental particle physics (3)
- Heavy Ions (3)
- Initial state radiation (3)
- Jets and Jet Substructure (3)
- Particle and resonance production (3)
- e+-e− Experiments (3)
- pp collisions (3)
- Beauty production (2)
- Bhabha (2)
- Charmonium (2)
- Cross section (2)
- Diagnostik (2)
- Electroweak Interaction (2)
- Früherkennung (2)
- Hadronic cross section (2)
- Heavy Quark Production (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Leptonic, semileptonic & radiative decays (2)
- Mammakarzinom (2)
- Muon anomaly (2)
- Nachsorge (2)
- Particle Correlations and Fluctuations (2)
- Particle correlations and fluctuations (2)
- Particle decays (2)
- Pb–Pb collisions (2)
- Pion form factor (2)
- Richtlinie (2)
- Single electrons (2)
- Superficial vein thrombosis (2)
- breast cancer (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- screening (2)
- 900 GeV (1)
- ALICE detector (1)
- Absolute branching fraction (1)
- Alcohol consumption (1)
- Angular distribution (1)
- Annihilation (1)
- Anti-nuclei (1)
- BESIII detector (1)
- Benign disorder (1)
- Blood pressure (1)
- Boosted Jets (1)
- Born cross section measurement (1)
- CP violation (1)
- CTLA-4 (1)
- Cancer (1)
- Cardiovascular biology (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charmonium (-like) (1)
- Clinical Trials and Observations (1)
- Collective Flow, (1)
- Comparison with QCD (1)
- Covariance matrix (1)
- Cross section measurements (1)
- D meson (1)
- D0 and D+ mesons (1)
- Dalitz decay (1)
- Dark photon (1)
- Dark sector (1)
- Decision making (1)
- Depression (1)
- Diagnostic markers (1)
- D⁰ meson (1)
- Effectivity (1)
- Electromagnetic amplitude (1)
- Electromagnetic form factor (1)
- Electromagnetic form factors (1)
- Electron-pion identification (1)
- Elliptic flow (1)
- Emotions (1)
- FOS: Physical sciences (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Flavor changing neutral currents (1)
- Flavor symmetries (1)
- Flavour Physics (1)
- Fondaparinux (1)
- Form factors (1)
- HBT (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hadrons (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- High Energy Physics - Experiment (hep-ex) (1)
- Hyperons (1)
- Immunology (1)
- Inclusive branching fraction (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Invariant Mass Distribution (1)
- Invisible decays (1)
- Ionisation energy loss (1)
- Jet Physics (1)
- Jet Substructure (1)
- K0S (1)
- Langerhans cell histiocytosis (1)
- Lemperle (1)
- Low-molecular-weight heparin (1)
- Lymphoid Neoplasia (1)
- Malignancy (1)
- Material budget (1)
- Mental health and psychiatry (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Neural network (1)
- Neutrinos (1)
- Nuclear modification factor (1)
- Observational (1)
- Observational studies (1)
- Oncology (1)
- PD-1 (1)
- PYTHIA (1)
- Particle phenomena (1)
- Pb–Pb (1)
- Phase (1)
- Planning target volume (1)
- Polarization (1)
- Production Cross Section (1)
- Prognostic markers (1)
- Properties of Hadrons (1)
- Proton (1)
- Proton–proton (1)
- Quantum chromodynamics (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- R value (1)
- Radiation induced diarrhoea (1)
- Radiotherapy (1)
- Rapidity Range (1)
- Rare decays (1)
- Rare disease (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- Risk assessment (1)
- SUV (1)
- Selenium administration in gynecologic radiation oncology (1)
- Semi-leptonic decays (1)
- Single muons (1)
- Strong amplitude (1)
- Systematic Uncertainty (1)
- TR (1)
- Techniques Electromagnetic calorimeters (1)
- Testosterone (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Treatment (1)
- Trigger (1)
- Triple quarkonia (1)
- Vector Boson Production (1)
- Venous thrombosis (1)
- W-exchange (1)
- Xenon-based gas mixture (1)
- Y (4260) (1)
- Y states (1)
- advanced melanoma (1)
- anti-angiogenic therapy (1)
- antibodies (1)
- antihelix shaping (1)
- b-cell lymphomas (1)
- bendamustine (1)
- branching fractions (1)
- center-of-mass energy (1)
- charmed baryon (1)
- charmonium-like states (1)
- chemotherapy regimen (1)
- chimeric antigen receptor t-cell therapy (1)
- chimeric antigen receptors (1)
- complete response (1)
- dE/dx (1)
- decay (1)
- decays (1)
- detector (1)
- dimuon (1)
- diphoton (1)
- discontinuation (1)
- disease progression (1)
- dynamic 18F-FDG PET/CT (1)
- e+e − annihilation (1)
- e+e⁻ − Experiments (1)
- e+e− annihilation (1)
- electron-positron collision (1)
- experimental results (1)
- fondaparinux (1)
- glioblastoma (1)
- hadron spectroscopy (1)
- hadronic events (1)
- heavy ion experiments (1)
- helicity amplitude analysis (1)
- hematopoietic stem cell transplantation (1)
- immune checkpoint blockade (1)
- inclusive J/ψ decays (1)
- leukapheresis (1)
- liver metastasis (1)
- low molecular weight heparin (1)
- luminosity (1)
- lymphoma (1)
- macrophage polarization (1)
- miRNAs (1)
- number of J/ψ events (1)
- otoplasty (1)
- pazopanib (1)
- protruding ear (1)
- quark gluon plasma (1)
- rituximab (1)
- second-line immunotherapy (1)
- soft tissue sarcoma (STS) (1)
- spectra (1)
- targeted therapy (1)
- tetraquark (1)
- therapy resistance (1)
- treatment (1)
- treatment resistance (1)
- trigger efficiency (1)
- tumor angiogenesis (1)
- two-tissue compartment model (1)
- uveal melanoma (1)
- venous thrombosis (1)
- ventral otoplasty (1)
- Λ+c baryon (1)
- Λc⁺ (1)
- Σ hyperon (1)
- ψ(3686) (1)
- √sN N = 2.76 TeV (1)
Institute
Epigenetic neural glioblastoma enhances synaptic integration and predicts therapeutic vulnerability
(2023)
Neural-tumor interactions drive glioma growth as evidenced in preclinical models, but clinical validation is nascent. We present an epigenetically defined neural signature of glioblastoma that independently affects patients survival. We use reference signatures of neural cells to deconvolve tumor DNA and classify samples into low- or high-neural tumors. High-neural glioblastomas exhibit hypomethylated CpG sites and upregulation of genes associated with synaptic integration. Single-cell transcriptomic analysis reveals high abundance of stem cell-like malignant cells classified as oligodendrocyte precursor and neural precursor cell-like in high-neural glioblastoma. High-neural glioblastoma cells engender neuron-to-glioma synapse formation in vitro and in vivo and show an unfavorable survival after xenografting. In patients, a high-neural signature associates with decreased survival as well as increased functional connectivity and can be detected via DNA analytes and brain-derived neurotrophic factor in plasma. Our study presents an epigenetically defined malignant neural signature in high-grade gliomas that is prognostically relevant.
The use of cardiac troponins (cTn) is the gold standard for diagnosing myocardial infarction. Independent of myocardial infarction (MI), however, sex, age and kidney function affect cTn levels. Here we developed a method to adjust cTnI levels for age, sex, and renal function, maintaining a unified cut-off value such as the 99th percentile. A total of 4587 individuals enrolled in a prospective longitudinal study were used to develop a model for adjustment of cTn. cTnI levels correlated with age and estimated glomerular filtration rate (eGFR) in males/females with rage = 0.436/0.518 and with reGFR = −0.142/−0.207. For adjustment, these variables served as covariates in a linear regression model with cTnI as dependent variable. This adjustment model was then applied to a real-world cohort of 1789 patients with suspected acute MI (AMI) (N = 407). Adjusting cTnI showed no relevant loss of diagnostic information, as evidenced by comparable areas under the receiver operator characteristic curves, to identify AMI in males and females for adjusted and unadjusted cTnI. In specific patients groups such as in elderly females, adjusting cTnI improved specificity for AMI compared with unadjusted cTnI. Specificity was also improved in patients with renal dysfunction by using the adjusted cTnI values. Thus, the adjustments improved the diagnostic ability of cTnI to identify AMI in elderly patients and in patients with renal dysfunction. Interpretation of cTnI values in complex emergency cases is facilitated by our method, which maintains a single diagnostic cut-off value in all patients.
Simple Summary: The introduction of BRAF/MEK-directed targeted therapy (TT) has significantly improved the management of patients with advanced BRAF-V600-mutant melanoma. Although resistance occurs, there is a subgroup of patients showing a complete response (CR) to TT and who maintain durable disease control. For these patients with durable CR, it is not clear whether it is safe to cease therapy. In this retrospective, multicenter study we have analyzed 37 patients who received TT and achieved a CR upon treatment. We identified 15 patients with a durable CR to TT. Overall, patients who discontinued TT (n = 26) were at higher risk of tumor progression compared to patients receiving ongoing TT. Sustained CR was however not restricted to patients with ongoing TT (n = 11) but was also found in patients who ceased TT (n = 4). Finally, our analysis indicated which patients with an initial CR might be most likely to maintain durable CR upon discontinuation of TT.
Abstract: The advent of BRAF/MEK inhibitors (BRAFi/MEKi) has significantly improved progression-free (PFS) and overall survival (OS) for patients with advanced BRAF-V600-mutant melanoma. Long-term survivors have been identified particularly among patients with a complete response (CR) to BRAF/MEK-directed targeted therapy (TT). However, it remains unclear which patients who achieved a CR maintain a durable response and whether treatment cessation might be a safe option in these patients. Therefore, this study investigated the impact of treatment cessation on the clinical course of patients with a CR upon BRAF/MEK-directed-TT. We retrospectively selected patients with BRAF-V600-mutant advanced non-resectable melanoma who had been treated with BRAFi ± MEKi therapy and achieved a CR upon treatment out of the multicentric skin cancer registry ADOReg. Data on baseline patient characteristics, duration of TT, treatment cessation, tumor progression (TP) and response to second-line treatments were collected and analyzed. Of 461 patients who received BRAF/MEK-directed TT 37 achieved a CR. TP after initial CR was observed in 22 patients (60%) mainly affecting patients who discontinued TT (n = 22/26), whereas all patients with ongoing TT (n = 11) maintained their CR. Accordingly, patients who discontinued TT had a higher risk of TP compared to patients with ongoing treatment (p < 0.001). However, our data also show that patients who received TT for more than 16 months and who discontinued TT for other reasons than TP or toxicity did not have a shorter PFS compared to patients with ongoing treatment. Response rates to second-line treatment being initiated in 21 patients, varied between 27% for immune-checkpoint inhibitors (ICI) and 60% for BRAFi/MEKi rechallenge. In summary, we identified a considerable number of patients who achieved a CR upon BRAF/MEK-directed TT in this contemporary real-world cohort of patients with BRAF-V600-mutant melanoma. Sustained PFS was not restricted to ongoing TT but was also found in patients who discontinued TT.
We report a measurement of the observed cross sections of e+ e− → J/ψX based on 3.21 fb − 1 of data accumulated at energies from 3.645 to 3.891 GeV with the BESIII detector operated at the BEPCII collider. In analysis of the cross sections, we measured the decay branching fractions of B(ψ(3686) → J/ψX) = (64.4 ± 0.6 ± 1.6)% and B(ψ(3770) → J/ψX) = (0.5 ± 0.2 ± 0.1)% for the first time. The energy-dependent line shape of these cross sections cannot be well described by two Breit-Wigner (BW) amplitudes of the expected decays ψ (3686) → J/ψX and ψ(3770) → J/ψX. Instead, it can be better described with one more BW amplitude of the decay R(3760)→ J/ψX. Under this assumption, we extracted the R (3760) mass M R (3760 ) = 3766.2 ± 3.8 ± 0.4 MeV/c2, total width Γ tot R ( 3760 ) = 22.2 ± 5.9 ± 1.4 MeV, and product of leptonic width and decay branching fraction
ΓeeR(3760) B[R(3760) → J/ψX] = (79.4 ± 85.5 ± 11.7) eV. The significance of the R(3760) is 5.3σ. The first uncertainties of these measured quantities are from fits to the cross sections and second systematic.
Glioblastoma multiforme (GBM) is treated by surgical resection followed by radiochemotherapy. Bevacizumab is commonly deployed for anti‐angiogenic therapy of recurrent GBM; however, innate immune cells have been identified as instigators of resistance to bevacizumab treatment. We identified angiopoietin‐2 (Ang‐2) as a potential target in both naive and bevacizumab‐treated glioblastoma. Ang‐2 expression was absent in normal human brain endothelium, while the highest Ang‐2 levels were observed in bevacizumab‐treated GBM. In a murine GBM model, VEGF blockade resulted in endothelial upregulation of Ang‐2, whereas the combined inhibition of VEGF and Ang‐2 leads to extended survival, decreased vascular permeability, depletion of tumor‐associated macrophages, improved pericyte coverage, and increased numbers of intratumoral T lymphocytes. CD206+ (M2‐like) macrophages were identified as potential novel targets following anti‐angiogenic therapy. Our findings imply a novel role for endothelial cells in therapy resistance and identify endothelial cell/myeloid cell crosstalk mediated by Ang‐2 as a potential resistance mechanism. Therefore, combining VEGF blockade with inhibition of Ang‐2 may potentially overcome resistance to bevacizumab therapy.
Orthotopic liver transplantation in human-immunodeficiency-virus-positive patients in Germany
(2012)
Objectives: This summary evaluates the outcomes of orthotopic liver transplantation (OLT) of HIV-positive patients in Germany.
Methods: Retrospective chart analysis of HIV-positive patients, who had been liver-transplanted in Germany between July 1997 and July 2011.
Results: 38 transplantations were performed in 32 patients at 9 German transplant centres. The reasons for OLT were end-stage liver disease (ESLD) and/or liver failure due to hepatitis C (HCV) (n = 19), hepatitis B (HBV) (n = 10), multiple viral infections of the liver (n = 2) and Budd-Chiari-Syndrome. In July 2011 19/32 (60%) of the transplanted patients were still alive with a median survival of 61 months (IQR (interquartile range): 41-86 months). 6 patients had died in the early post-transplantation period from septicaemia (n = 4), primary graft dysfunction (n = 1), and intrathoracal hemorrhage (n = 1). Later on 7 patients had died from septicaemia (n = 2), delayed graft failure (n = 2), recurrent HCC (n = 2), and renal failure (n = 1). Recurrent HBV infection was efficiently prevented in 11/12 patients; HCV reinfection occurred in all patients and contributed considerably to the overall mortality.
Conclusions: Overall OLT is a feasible approach in HIV-infected patients with acceptable survival rates in Germany. Reinfection with HCV still remains a major clinical challenge in HIV/HCV coinfection after OLT.
The KASCADE-Grande experiment has significantly contributed to the current knowledge about the energy spectrum and composition of cosmic rays for energies between the knee and the ankle. Meanwhile, post-LHC versions of the hadronic interaction models are available and used to interpret the entire data set of KASCADE-Grande. In addition, a new, combined analysis of both arrays, KASCADE and Grande, was developed significantly increasing the accuracy of the shower observables. First results of the new analysis with the entire data set of the KASCADE-Grande experiment will be the focus of this contribution.
Using 7.33 fb−1 of e+e− collision data collected by the BESIII detector at center-of-mass energies between 4.128 and 4.226~GeV, we observe for the first time the decay D±s→ωπ±η with a statistical significance of 7.6σ. The measured branching fraction of this decay is (0.54±0.12±0.04)%, where the first uncertainty is statistical and the second is systematic.
Using a sample of (10.09±0.04)×109 J/ψ events collected with the BESIII detector, a partial wave analysis of J/ψ→γη′η′ is performed.The masses and widths of the observed resonances and their branching fractions are reported. The main contribution is from J/ψ→γf0(2020) with f0(2020)→η′η′, which is found with a significance of greater than 25σ. The product branching fraction B(J/ψ → γf0(2020))⋅B(f0(2020) → η′η′ is measured to be (2.63±0.06(stat.) + 0.31−0.46(syst.))×10−4.
We present the first experimental search for the rare charm decay D0→π0ν¯ν. It is based on an e+e− collision sample consisting of 10.6×10^6 pairs of D0¯D0 mesons collected by the BESIII detector at √s=3.773 GeV, corresponding to an integrated luminosity of 2.93 fb^−1. A data-driven method is used to ensure the reliability of the background modeling. No significant D0→π0ν¯ν signal is observed in data and an upper limit of the branching fraction is set to be 2.1×10^-4 at the 90% confidence level. This is the first experimental constraint on charmed-hadron decays into dineutrino final states.